Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-02 20:30 | 2026-06-30 | PYXS | Pyxis Oncology, Inc. | Dupont Jakob | Director | OPT+S | $3.06 | 35,000 | $107,100 | 38,741 |
| 2026-07-02 20:05 | 2026-06-30 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Officer | OPT+S | $20.00 | 4,654 | $93,080 | 51,776 |
| 2026-07-02 20:54 | 2026-06-30 | QURE | uniQure N.V. | Kaye Jack | Director | OPT+S | $46.44 | 21,167 | $983,029 | 25,996 |
| 2026-07-02 20:35 | 2026-07-01 | GNLX | GENELUX Corp | Smither John W | Director | SELL | $2.91 | 12,000 | $34,898 | 91,403 |
| 2026-07-02 21:00 | 2026-07-01 | ORMP | ORAMED PHARMACEUTICALS INC. | Hexter Joshua | Officer | OPT+S | $4.46 | 137,000 | $611,431 | 1,023,384 |
| 2026-07-02 21:00 | 2026-07-01 | ORMP | ORAMED PHARMACEUTICALS INC. | Gabay Avraham | Officer | SELL | $4.51 | 73,360 | $330,744 | 671,785 |
| 2026-07-02 20:32 | 2026-07-02 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $552.56 | 8,300 | $4,586,275 | 45,172 |
| 2026-07-02 20:31 | 2026-07-01 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $543.66 | 9,500 | $5,164,789 | 40,513 |
| 2026-07-02 21:20 | 2026-07-01 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer | SELL | $84.92 | 7,500 | $636,900 | 377,830 |
| 2026-07-02 20:42 | 2026-06-30 | SION | Sionna Therapeutics, Inc. | ORBIMED ADVISORS LLC | Director | SELL | $45.50 | 115,844 | $5,270,902 | 2,555,877 |
| 2026-07-03 01:32 | 2026-07-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | Director, Officer | SELL | $87.69 | 15,000 | $1,315,347 | 582,540 |
| 2026-07-03 01:33 | 2026-07-01 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Officer | OPT+S | $87.70 | 8,334 | $730,896 | 0 |
| 2026-07-03 01:33 | 2026-07-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | Officer | OPT+S | $87.74 | 7,500 | $658,040 | 97,994 |
| 2026-07-03 00:31 | 2026-06-30 | IMNM | Immunome Inc. | Barchas Isaac | Director | SELL | $21.85 | 201,050 | $4,393,023 | 208,504 |
| 2026-07-03 00:15 | 2026-06-30 | STTK | Shattuck Labs, Inc. | Pandite Arundathy N. | Officer | SELL | $7.01 | 30,000 | $210,300 | 136,219 |
| 2026-07-03 00:17 | 2026-06-30 | STTK | Shattuck Labs, Inc. | Shukla Abhinav A. | Officer | OPT+S | $7.08 | 23,465 | $166,132 | 86,380 |
| 2026-07-02 23:45 | 2026-06-30 | BOLD | Boundless Bio, Inc. | TANG KEVIN | 10% owner | BUY | $2.50 | 107,463 | $268,883 | 2,641,308 |
| 2026-07-02 23:23 | 2026-07-01 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Officer | OPT+S | $29.59 | 27,000 | $798,908 | 115,743 |
| 2026-07-02 23:06 | 2026-06-30 | NKTR | NEKTAR THERAPEUTICS | Zalevsky Jonathan | Officer | SELL | $70.00 | 5,681 | $397,670 | 9,756 |
| 2026-07-02 23:00 | 2026-07-01 | SEPN | Septerna, Inc. | Long Daniel D. | Officer | OPT+S | $34.36 | 3,333 | $114,528 | 96,412 |
| 2026-07-02 23:02 | 2026-06-30 | INM | InMed Pharmaceuticals Inc. | Vivo Opportunity, LLC | 10% owner | BUY | $1.55 | 6,551 | $10,148 | 73,135 |
| 2026-07-02 23:03 | 2026-06-30 | ROIV | Roivant Sciences Ltd. | Fitzgerald Meghan | Director | OPT+S | $34.90 | 10,000 | $349,000 | 42,963 |
| 2026-07-02 22:42 | 2026-07-01 | NGNE | Neurogene Inc. | Cvijic Christine Mikail | Director, Officer | SELL | $34.71 | 4,800 | $166,586 | 88,840 |
| 2026-07-02 22:11 | 2026-07-01 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | BUY | $71.97 | 1,712 | $123,220 | 491,712 |
| 2026-07-02 22:01 | 2026-07-01 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | Officer | SELL | $120.00 | 2,721 | $326,520 | 3,114 |
| 2026-07-02 22:02 | 2026-07-02 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | Officer | OPT+S | $23.56 | 11,008 | $259,366 | 13,579 |
| 2026-07-02 21:47 | 2026-06-30 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Officer | OPT+S | $15.99 | 37,179 | $594,578 | 135,202 |
| 2026-07-02 21:47 | 2026-07-02 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $554.61 | 9,500 | $5,268,781 | 40,513 |
| 2026-07-02 21:17 | 2026-07-01 | CYTK | CYTOKINETICS INC | Lee Sung | Officer | OPT+S | $87.79 | 1,112 | $97,622 | 63,221 |
| 2026-07-02 21:19 | 2026-07-01 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | OPT+S | $85.80 | 15,000 | $1,287,000 | 58,555 |
| 2026-07-02 20:45 | 2026-06-30 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Director | SELL | $45.50 | 115,844 | $5,270,902 | 2,555,877 |
| 2026-07-02 20:03 | 2026-07-01 | AGIO | AGIOS PHARMACEUTICALS, INC. | Gheuens Sarah | Officer | OPT+S | $37.56 | 4,007 | $150,503 | 84,645 |
| 2026-07-02 19:00 | 2026-07-01 | OTLC | Oncotelic Therapeutics, Inc. | Trieu Vuong | Director, Officer, 10% owner | BUY | $0.04 | 240,000 | $10,344 | 94,124,319 |
| 2026-07-02 17:37 | 2026-07-01 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP | 10% owner | BUY | $3.30 | 3,959 | $13,065 | 82,556 |
| 2026-07-02 16:57 | 2026-07-01 | EBS | Emergent BioSolutions Inc. | Williams Paul Anthony | Officer | SELL | $8.40 | 3,000 | $25,200 | 159,098 |
| 2026-07-01 20:10 | 2026-06-30 | RAPP | Rapport Therapeutics, Inc. | Gault Cheryl | Officer | SELL | $41.58 | 10,000 | $415,798 | 149,914 |
| 2026-07-01 20:27 | 2026-06-29 | BIOA | BioAge Labs, Inc. | Barton Shane | Officer | OPT+S | $25.20 | 62,566 | $1,576,751 | 0 |
| 2026-07-01 20:24 | 2026-06-30 | ZLAB | Zai Lab Ltd | Du Ying | Director, Officer | OPT+S | $18.53 | 7,026 | $130,220 | 1,203,784 |
| 2026-07-01 20:20 | 2026-06-30 | PCSA | Processa Pharmaceuticals, Inc. | Guy Wendy | Officer | BUY | $1.93 | 2,436 | $4,701 | 14,394 |
| 2026-07-02 01:52 | 2026-06-29 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | Director, Officer, 10% owner | SELL | $3.03 | 7,400 | $22,422 | 98,589 |
| 2026-07-02 01:30 | 2026-07-01 | ORKA | Oruka Therapeutics, Inc. | Fairmount Funds Management LLC | Director, 10% owner | SELL | $84.43 | 3,553,410 | $300,014,406 | 1,131,954 |
| 2026-07-02 00:09 | 2026-06-29 | FTH | Sensei Biotherapeutics, Inc. | STEPHENSON BRIAN C | Officer | BUY | $23.92 | 13,634 | $326,128 | 46,688 |
| 2026-07-01 23:58 | 2026-07-01 | ORKA | Oruka Therapeutics, Inc. | Sandler Laura Lee | Officer | OPT+S | $94.42 | 5,000 | $472,079 | 236,384 |
| 2026-07-01 23:30 | 2026-07-01 | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | Director, Officer, 10% owner | OPT+S | $240.25 | 49,666 | $11,932,257 | 7,229 |
| 2026-07-01 23:33 | 2026-06-29 | TBPH | Theravance Biopharma, Inc. | Samaha Eli | 10% owner | SELL | $17.20 | 336,697 | $5,791,559 | 9,174,453 |
| 2026-07-01 23:06 | 2026-06-29 | PHVS | Pharvaris N.V. | Schikan Johannes Gerardus Christiaan Petrus | Director | SELL | $35.41 | 37,600 | $1,331,495 | 315,167 |
| 2026-07-01 23:17 | 2026-06-29 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP | 10% owner | BUY | $3.40 | 32,591 | $110,695 | 78,597 |
| 2026-07-01 23:02 | 2026-06-29 | PHVS | Pharvaris N.V. | Lesage Anne | Officer | OPT+S | $35.39 | 76,172 | $2,695,453 | 93,969 |
| 2026-07-01 23:04 | 2026-06-30 | CTNM | Contineum Therapeutics, Inc. | Stengone Carmine N. | Director, Officer | OPT+S | $16.01 | 10,000 | $160,080 | 17,217 |
| 2026-07-01 23:04 | 2026-06-30 | CTNM | Contineum Therapeutics, Inc. | Watkins Tim | Officer | OPT+S | $16.02 | 10,833 | $173,590 | 8,961 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.